{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-027383","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.254270+00:00","generated_at":"2026-05-31T08:29:00.989725+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx Pharmaceuticals CEO Stephen Willard recommends new CEO with commercial pharma experience; search initiated","bullets":["Stephen Willard, CEO of NRx Pharmaceuticals, recommended that the company's shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience.","The company has initiated a search for a new CEO possessing the desired qualifications; Mr. Willard will continue as CEO during the search.","Mr. Willard stated his recommendation is not the result of any disagreement regarding the company's operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-027383","json":"https://secwatch.observer/filing/0001437749-24-027383.json","markdown":"https://secwatch.observer/filing/0001437749-24-027383.md","text":"https://secwatch.observer/filing/0001437749-24-027383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924027383/0001437749-24-027383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924027383/nrxp20240820_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:29:00.989725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}